Start Your Risk-Free Subscription

Login

The Daily Biopharmaceutical News Source

Advanced Search

Celgene Plunks Down Potential $935M for Avila Therapeutics

By Marie Powers
Staff Writer

Friday, January 27, 2012

Robert Hugin, chairman and CEO of Celgene Corp., wasn't kidding when he told attendees at this month's J.P. Morgan Healthcare Conference that 2011 was a "year of momentum" for the giant biotech. (See BioWorld Today, Jan. 10, 2012.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription

»

Login or register to post comments

Customer Service: In the U.S. and Canada: 1-800-688-2421
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA

Part of Thompson Media Group LLC
Thompson.com | Sheshunoff.com | ASPratt.com | AHCMedia.com | BioWorld.com | CMEweb.com | ThePerformanceInstitute.org | ASMIweb.com

Editorial Guidelines

For Site License Discounts, please contact Customer Service at (800) 688-2421 or customerservice@bioworld.com.